About Us
Patient Care is Our Priority
Our Mission
At the Blood and Marrow Transplantation & Cellular Therapy Division, we strive to improve the health and well-being of our patients by delivering expert and compassionate care. We conduct innovative clinical and translational research to deepen our understanding of the biology and immunology of transplantation and cellular therapies. Our mission extends to training the next generation of clinicians, scientists, and healthcare professionals, ensuring the continued advancement of our field and the highest standards of patient care.
Cutting-edge facilities and innovative treatments
The BMT-CT Division at Stanford University is fully accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and is a member of the BMT Clinical Trials Network of the United States. As part of the Stanford Medicine Cancer Center we are dedicated to the advancement of cancer therapy.
We are united in our mission to deliver state-of-the-art treatments and empathetic care for patients facing a diverse array of malignant and non-malignant disorders. Each year, we have the honor of caring for over 450+ blood and marrow transplantation patients and more than 250 cellular therapy recipients, contributing to a total of over 10,500 transplants and cellular therapies since our division's inception.
Our program provides autologous and allogeneic hematopoietic cell transplants tailored to each individual’s specific need. We provide all allogeneic source options including HLA-matched sibling donors, haploidentical donors, cord blood, and unrelated donors from the National Marrow Donor Program. This range of treatment options reflects our unwavering commitment to addressing the unique needs of every patient.
In addition to our comprehensive transplantation services, we have introduced several pioneering therapies to further enhance patient care. Since the launch of our Chimeric Antigen Receptor (CAR) T-cell Therapy in 2016, we have witnessed significant advancements in our cellular therapies portfolio, which continues to expand. In 2024, we broadened our BMT-CT division with the introduction of Tumor Infiltrating Lymphocyte (TIL) Therapy, an innovative form of immunotherapy that utilizes the body’s own immune cells by extracting and expanding T cells that have infiltrated the patient’s solid tumors, demonstrating their capacity to recognize and attack cancer cells. Lastly, our Cellular Immune Tolerance (CIT) Program, established in 2023, has made notable progress in providing advanced cellular immune therapy for patients with autoimmune conditions or those undergoing organ transplantation.
If you are interested in more information about being a volunteer bone marrow or stem cell donor, visit the National Marrow Donor Program.
